Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Genelux (GNLX) Research & Development (2022 - 2025)

Genelux has reported Research & Development over the past 4 years, most recently at $5.7 million for Q4 2025.

  • Quarterly results put Research & Development at $5.7 million for Q4 2025, down 13.28% from a year ago — trailing twelve months through Dec 2025 was $21.7 million (up 14.08% YoY), and the annual figure for FY2025 was $19.9 million, up 4.49%.
  • Research & Development for Q4 2025 was $5.7 million at Genelux, up from $4.7 million in the prior quarter.
  • Over the last five years, Research & Development for GNLX hit a ceiling of $6.5 million in Q4 2024 and a floor of $2.4 million in Q3 2022.
  • Median Research & Development over the past 4 years was $4.1 million (2024), compared with a mean of $4.0 million.
  • Biggest five-year swings in Research & Development: skyrocketed 68.56% in 2023 and later fell 13.28% in 2025.
  • Genelux's Research & Development stood at $2.5 million in 2022, then skyrocketed by 68.56% to $4.2 million in 2023, then skyrocketed by 56.73% to $6.5 million in 2024, then fell by 13.28% to $5.7 million in 2025.
  • The last three reported values for Research & Development were $5.7 million (Q4 2025), $4.7 million (Q3 2025), and $4.8 million (Q2 2025) per Business Quant data.